Sign in

Alzheimer disease

Current status: No cure yet

A brain disease that slowly harms memory and thinking, and the most common cause of dementia in older people. Medicines cannot stop it, but some can keep the symptoms from getting worse for a while. Most people who get it are over 65, and the risk rises with age: about 1 in 6 people over 80 has it or another type of dementia. The changes in the brain start many years before the first signs appear.

Read more about Alzheimer disease
Where research stands todayUpdated 18 Nov 2026

Trial-stage treatments and research studies you can joinOpen trials for referral

Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.

Filters

Country
City
Distance is calculated in your browser. Your city is not sent to us.
Type
Get notified of new trialsGermany, all cities, all phases
Your ageShows only trials that take people your age.
Phase
  1. Trial-stage treatmentPhase 3Taking people
    Tests KarXT with KarX-EC for memory and thinking problems in Alzheimer's disease

    Tests KarXT with KarX-EC against a placebo in people with mild to moderate Alzheimer's.

    Bad Homburg, GermanyAlso Chemnitz, Cologne, Munich, UlmAge 60 to 85
  2. Trial-stage treatmentPhase 3Taking people
    Testing KarXT with KarX-EC for memory problems in Alzheimer's disease

    Tests KarXT with KarX-EC against placebo in adults with mild to moderate Alzheimer's disease.

    Aachen, GermanyAlso Berlin, Mainz, MannheimAge 60 to 85
  3. Trial-stage treatmentPhase 2Taking people
    Tests RO7568282 against a placebo in early Alzheimer's disease

    Compares RO7568282 with a placebo in people in early Alzheimer's disease.

    Aachen, GermanyAlso Berlin, Freiburg im Breisgau, JenaAge 50 to 90
  4. Trial-stage treatmentPhase 3
    Long-Term Safety Study of KarXT for Psychosis in Alzheimer's Disease

    Tests KarXT, a long-term safety study in people with Alzheimer's-related psychosis.

    Frankfurt Am Main, GermanyAlso HomburgAge 55 to 90
  5. Trial-stage treatmentPhase 3Soon in Germany
    Long-term study of KarXT and KarX-EC for agitation in Alzheimer's disease

    Tests KarXT and KarX-EC over time in people with Alzheimer's-related agitation.

    Düsseldorf, GermanyAlso Halle, WesterstedeAge 55 to 90
  6. Trial-stage treatmentPhase 2/3Taking people
    EXV-802 and EXV-801 for agitation in people with Alzheimer's disease dementia

    Tests EXV-802 and EXV-801 against placebo for agitation in Alzheimer's disease dementia.

    Berlin, GermanyAlso Chemnitz, EbersbergAge 55 to 90
  7. Trial-stage treatmentPhase 2Taking people
    Testing SAR448851, a daily pill, in people with early Alzheimer's disease

    Tests SAR448851 against placebo in people with early Alzheimer's disease.

    Berlin, GermanyAlso Bremen, Cologne, HanoverAge 55 to 85
  8. Trial-stage treatmentPhase 3Soon in Germany
    Tests KarXT with KarX-EC for agitation in Alzheimer's disease

    Tests KarXT with KarX-EC against placebo in adults with Alzheimer's-related agitation.

    Düsseldorf, GermanyAlso Halle, WesterstedeAge 55 to 90
  9. Trial-stage treatmentPhase 3
    KarXT Tested for Psychosis in People With Alzheimer's Disease

    Tests KarXT against placebo in adults with Alzheimer's and psychosis.

    Frankfurt Am Main, GermanyAge 55 to 90
  10. Trial-stage treatmentPhase 2This trial only enrols participants with Down syndromeSoon in Germany
    Mivelsiran Tested in Early Down Syndrome-Associated Alzheimer's Disease

    Tests mivelsiran against placebo in adults with early Down syndrome-associated Alzheimer's disease.

    Bremen, GermanyAlso MunichAge 40 to 55
  11. Trial-stage treatmentPhase 3
    Tests KarXT for psychosis linked to Alzheimer's disease

    Tests KarXT against placebo in people with Alzheimer's-related psychosis to prevent relapse.

    Bayreuth, GermanyAlso Böblingen, HomburgAge 55 to 90
  12. Trial-stage treatmentPhase 2/3Taking people
    Tests remternetug in people with an Alzheimer's-causing gene mutation

    Tests remternetug against placebo in adults with a gene mutation causing early Alzheimer's.

    Munich, GermanyAlso TübingenAge 18+
  13. Trial-stage treatmentPhase 2/3Taking people
    Tests remternetug in people at risk for early-onset familial Alzheimer disease

    Tests remternetug against placebo in adults with a genetic mutation causing Alzheimer disease.

    Munich, GermanyAlso TübingenAge 18+
  14. Trial-stage treatmentSoon in Germany
    Low-dose brain radiation as a possible treatment for early Alzheimer's disease

    Tests low-dose whole-brain radiation in people with early Alzheimer's disease.

    Düsseldorf, GermanyAge 50+
  15. Trial-stage treatmentPhase 1/2Taking people
    Tests NSC001 for safety in mild to moderate Alzheimer's disease

    Tests NSC001, compared with placebo, in adults with mild to moderate Alzheimer's disease.

    Altenburg, GermanyAlso Bad Homburg, Bochum, MannheimAge 50 to 85
  16. Research studyTaking people
    Eye pupil measurements in virtual reality for memory problems and depression

    Tests whether pupil responses in virtual reality reveal cognitive impairment in adults.

    München, GermanyAge 18 to 80
  17. Trial-stage treatmentPhase 2/3Taking people
    Testing Treatments to Slow Early Alzheimer's in People with Inherited Gene Changes

    Tests investigational drugs against placebo in adults with inherited Alzheimer's gene mutations.

    GermanyAge 18+
  18. Research studyTaking people
    Registry following transcranial pulse stimulation treatment for Alzheimer's disease in Germany

    Collects safety and effect data on pulse wave stimulation for people with Alzheimer's disease.

    Bonn, GermanyAlso Kempen, Neuss, Oldenburg, Potsdam, UlmAge 18 to 85
  19. Research studyTaking people
    Studies biomarkers that may predict Alzheimer's in people with inherited mutations

    Looks for signs that may predict Alzheimer's disease in adults carrying a gene mutation.

    Munich, GermanyAlso TübingenAge 18+
  20. Trial-stage treatmentTaking people
    Spermidine supplement and sleep in older adults with memory concerns or mild cognitive impairment

    Tests spermidine against placebo for sleep and memory in older adults with cognitive decline.

    Greifswald, GermanyAge 55 to 75

Search the publications

The results open on the publications page in a new tab, so this page stays as it is.

Lists with this disease filtered

Where treatment stands

In the EU, lecanemab was first approved in April 2025 and donanemab in September 2025.

Approved: 12

Officially approved for this disease in the EU, the US, Switzerland or France.

Human testing stage: 29

Being tested in people. Many treatments at this stage are never approved.

Animal testing stage: 5

Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.

Lab research stage: 1

Worked on cells in the lab in a study published in the last 12 months. Most early ideas never reach people.

Support organisations

Patient organisations and helplines in Germany, for you and your family.

Alzheimer disease organisations in Germany

  • Alzheimer Angehörigen-Initiative e.V.

    Supports relatives of people with dementia in Berlin with counselling, self-help groups, care courses and day care.

  • Alzheimer Gesellschaft Baden-Württemberg e.V. Selbsthilfe Demenz

    Dementia self-help association in Baden-Württemberg offering counselling, information and FTD-specific online support groups and seminars for relatives.

  • Alzheimer Gesellschaft Berlin e.V.

    Berlin association for people with dementia and their relatives, offering counselling, self-help groups, information guides and volunteer activities.

  • Alzheimer Gesellschaft Berlin e.V. Selbsthilfe Demenz

    Offers counselling and self-help for people living with dementia and their relatives in Berlin.

  • Alzheimer Gesellschaft Brandenburg e.V. Selbsthilfe Demenz

    Represents people with dementia and their relatives in Brandenburg, with counselling, self-help and events.

  • Alzheimer Gesellschaft Hamburg e.V.

    Hamburg self-help organisation for people with dementia and their relatives, offering counselling, relative groups and courses, including FTD courses.

  • Alzheimer Gesellschaft München e.V.

    Munich association offering counselling, discussion groups, carer training and volunteer home support for people with dementia and their relatives.

  • Deutsche Alzheimer Gesellschaft e.V. Selbsthilfe Demenz

    National Alzheimer association: Alzheimer-Telefon advice line, email advice, nationwide finder for local help, online forums, carer seminars, podcast, young-onset dementia support.

  • Deutsche Alzheimer Gesellschaft Landesverband Mecklenburg-Vorpommern e.V. Selbsthilfe Demenz

    Rostock-based state association for people with dementia and their relatives in Mecklenburg-Vorpommern, offering counselling, self-help groups and advocacy.

  • Hans und Ilse Breuer-Stiftung

    Non-profit foundation for people with dementia and relatives: counselling, the StattHaus Offenbach dementia centre with day care, carer seminars, and research funding.

  • Landesverband der Alzheimer Gesellschaften Nordrhein-Westfalen e. V. Selbsthilfe Demenz

    State association in North Rhine-Westphalia for people with dementia and their families, offering an Alzheimer helpline, caregiver training and self-help support.

  • Wegweiser Demenz

    Federal family ministry portal: dementia information, advice for carers, address databases of support services and a map of Local Alliances for people with dementia.

General support in Germany

  • TelefonSeelsorge Deutschland

    Free, anonymous 24/7 crisis and emotional support line across Germany (0800 111 0 111, 0800 111 0 222, 116 123), plus chat and e-mail.

  • gesund.bund.de

    The German Federal Ministry of Health's portal providing reliable, quality-assured health information on diseases, care and prevention.

  • Stiftung Unabhängige Patientenberatung Deutschland (UPD)

    Statutory independent foundation giving free advice to patients in Germany on health and health-law questions, including patient rights.

International organisations

  • Alzheimer's Association

    Free 24/7 Helpline (interpreters for 200+ languages), care consultations with dementia experts, local chapters, Community Resource Finder, ALZConnected online community.

  • Alzheimer's Drug Discovery Foundation

    Funds the early work on new Alzheimer's medicines, in universities and companies.

  • BrightFocus Foundation

    US nonprofit that funds research and provides public information on Alzheimer's disease, macular degeneration and glaucoma.

  • Dementia Alliance International (DAI)

    Organisation for people with a dementia diagnosis: free online peer support groups, webinars, Brain Health Hub, resources for care partners.

Frontlight Community

Alzheimer disease community in Germany

People living with Alzheimer disease and those close to them share what they went through. Posts are not medical advice: ask your doctor about your own treatment.

Offer tissue or data

There are three ways to help research move faster.

Give tissue or bloodA biobank stores your sample so many research teams can use it.See open programmes
Share your health dataA patient registry collects your health data, without your name, for research.How to join
Take part as a healthy volunteerStudies also need people without the disease, for comparison. Family and friends can help.Volunteer

Approved treatments

12 medicines are approved for Alzheimer disease in at least one of the places we checked. An approval in one place does not mean the medicine is offered or paid for where you live.

Checked on 18 Nov 2026 in the official lists of the US (FDA), the EU (European Commission and EMA) and Switzerland (Swissmedic), which we read every day. The lists of Japan (PMDA, approvals since April 2004), France (ANSM, medicines approved in France only) and Taiwan (TFDA) were checked on 11 Nov 2026. For Canada (Health Canada) and Singapore (HSA) we checked only whether a medicine is sold there, not what for. The French ratings are the opinions of the HAS Transparency Committee, from the French public medicines database (base de données publique des médicaments, newest opinion 10 Dec 2025). 4 uncertain matches are left out. Other countries' own approvals were not checked.

“Miracle cure” fact checker

Social media spreads misinformation. Paste here what you read, and we'll tell you whether there is scientific evidence behind it.

What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.

Before you pay for anything, ask three things

  1. Is there a published study in people?
  2. Can I have the full price in writing?
  3. What does my doctor say?

“Cures” others already fact-checked

See all 2

About Alzheimer disease

Sources: NHS, MedlinePlus, Archives of Neurology

A brain disease that slowly harms memory and thinking, and the most common cause of dementia in older people. Medicines cannot stop it, but some can keep the symptoms from getting worse for a while. Most people who get it are over 65, and the risk rises with age: about 1 in 6 people over 80 has it or another type of dementia. The changes in the brain start many years before the first signs appear.

What is it?

Alzheimer's is the most common cause of dementia: a steady loss of memory, thinking and other mental abilities. Proteins build up in and around brain cells. One protein (amyloid) forms clumps around the cells, another (tau) forms tangles inside them. Over time parts of the brain shrink, usually the memory areas first. These changes begin many years before any signs. It is not a normal part of getting older.

Most people who get it are over 65, and the risk rises with age: about 1 in 14 people over 65 and 1 in 6 over 80 have Alzheimer's or another type of dementia. Genes usually raise the risk only a little. In a few families a single gene causes it, and then it is much more likely to be passed on.

The first signs

The signs come on slowly over several years and are sometimes taken for normal ageing.

  • forget recent conversations or events;
  • misplace things and forget the names of places and objects;
  • struggle to find the right word, or ask the same questions again and again;
  • find decisions harder and become more hesitant about trying new things;
  • feel anxious, agitated or confused at times.

How doctors find out

There is no simple, reliable test. The doctor checks your general health, may order blood tests and ask about your medicines to rule out other causes, and asks you to do some memory and thinking tasks. You may then be sent to a specialist, who may work at a memory clinic, for more tests such as a brain scan (CT or MRI). Finding out can take many months and several appointments.

Current treatment

Symptom medicines (e.g. donepezil) plus support

Will it get worse?

Yes. It is a progressive illness: the symptoms get worse slowly over several years. It gets worse slowly, at a different pace for each person. In the middle stage people usually need support with everyday living, such as help with eating, washing, getting dressed and using the toilet. In the severe stages they may need full-time care. People may live for several years after the signs begin, but this varies a lot. Alzheimer's shortens life, though many people with it die of something else.

Medicines: what helps, and what to watch for

Medicines cannot cure Alzheimer's, but some can ease the symptoms for a time. Donepezil, galantamine and rivastigmine raise acetylcholine, a brain chemical that helps nerve cells pass messages; they are used in the early and middle stages. Memantine works in a different way and is used when the disease is moderate or severe.

Good to know:

  • specialists, such as psychiatrists or neurologists, can prescribe these medicines; your family doctor may prescribe them on a specialist's advice;
  • feeling sick, being sick and losing your appetite can be side effects, and they usually get better after about 2 weeks;
  • memantine can cause headaches, dizziness and constipation, which usually pass;
  • for aggression or extreme distress, other ways of coping are tried first; antipsychotic medicines have serious side effects, so they should be used at the lowest dose for the shortest time possible.

Exercise and therapy help too

Some treatments without medicines can help memory, problem solving, mood and wellbeing:

  • cognitive stimulation therapy: group activities and exercises for memory and problem solving;
  • cognitive rehabilitation: working with a professional, such as an occupational therapist, and a relative or friend towards a personal goal, like using a mobile phone;
  • reminiscence and life story work: talking about the past with the help of photos, objects or music.

Exercise regularly, for example with a daily walk, gardening, tai chi or dancing.

Is there a cure?

Not yet. No treatment can stop the disease today.

See the 902 trials you can join

Median survival

About 3 to 8 years after diagnosis, depending on age at diagnosis

Measured in: Participants of the Baltimore Longitudinal Study of Aging older than 55, followed 1985–1999

The figures behind it

Baltimore Longitudinal Study of Aging (participants older than 55, followed 1985–1999): median survival 8.3 years when Alzheimer disease was diagnosed at age 65, down to 3.4 years when it was diagnosed at age 90; no significant difference between men and women.